{"id":61993,"date":"2026-03-31T19:31:57","date_gmt":"2026-03-31T11:31:57","guid":{"rendered":"https:\/\/flcube.com\/?p=61993"},"modified":"2026-03-31T19:31:58","modified_gmt":"2026-03-31T11:31:58","slug":"biocytogen-licenses-rennano-antibody-platform-to-japans-taisho-pharmaceutical-in-strategic-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61993","title":{"rendered":"Biocytogen Licenses RenNano Antibody Platform to Japan&#8217;s Taisho Pharmaceutical in Strategic Partnership"},"content":{"rendered":"\n<p><strong>Biocytogen Pharmaceuticals (Beijing) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688796:SHA\">SHA: 688796<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>) has announced a <strong>licensing agreement<\/strong> with <strong>Taisho Pharmaceutical Co., Ltd.<\/strong>, granting the Japanese pharmaceutical company access to Biocytogen&#8217;s proprietary <strong>RenNano fully human heavy chain-only antibody (HCAbs) discovery platform<\/strong> for internal research and development programs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-summary\">Deal Structure Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Company<\/strong><\/td><td>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Taisho Pharmaceutical Co., Ltd. (Japan)<\/td><\/tr><tr><td><strong>Technology Licensed<\/strong><\/td><td>RenNano fully human heavy chain-only antibody (HCAbs) discovery platform<\/td><\/tr><tr><td><strong>Key Asset<\/strong><\/td><td>RenNano fully human nanobody mouse<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>In vivo generation and screening of fully human heavy-chain-only antibodies<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Undisclosed<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>Downstream antibody discovery and research advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-overview\">Technology Platform Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RenNano Platform:<\/strong> Proprietary fully human heavy chain-only antibody discovery system<\/li>\n\n\n\n<li><strong>Nanobody Mouse:<\/strong> Genetically engineered mouse model capable of generating fully human HCAbs in vivo<\/li>\n\n\n\n<li><strong>Technical Advantage:<\/strong> Enables direct in vivo screening and optimization of nanobody candidates<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Heavy chain-only antibodies offer superior tissue penetration and stability compared to conventional antibodies<\/li>\n\n\n\n<li><strong>Discovery Efficiency:<\/strong> Streamlines antibody discovery process from target identification to lead candidate selection<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-implications\">Strategic Partnership Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Biocytogen<\/strong><\/td><td>Revenue diversification through platform licensing; validation of RenNano technology by established Japanese pharma<\/td><\/tr><tr><td><strong>Taisho Pharmaceutical<\/strong><\/td><td>Access to cutting-edge antibody discovery capabilities without internal platform development costs<\/td><\/tr><tr><td><strong>Antibody Therapeutics Market<\/strong><\/td><td>Accelerated development of novel nanobody-based therapeutics for complex disease targets<\/td><\/tr><tr><td><strong>China-Japan Biotech Collaboration<\/strong><\/td><td>Strengthens cross-border innovation partnerships in advanced therapeutic modalities<\/td><\/tr><tr><td><strong>Investors<\/strong><\/td><td>Demonstrates monetization potential of Biocytogen&#8217;s proprietary technology platforms beyond internal pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The partnership represents a significant validation of Biocytogen&#8217;s RenNano platform, as Taisho Pharmaceutical joins the growing list of global pharmaceutical companies leveraging Chinese biotech innovation platforms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-analysis\">Market Context Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Nanobody Market Growth<\/strong><\/td><td>Global nanobody market projected to exceed USD 10 billion by 2030, driven by advantages in targeting difficult epitopes<\/td><\/tr><tr><td><strong>Platform Licensing Trend<\/strong><\/td><td>Increasing preference among pharma companies to license specialized discovery platforms rather than build internally<\/td><\/tr><tr><td><strong>China Biotech Export<\/strong><\/td><td>Represents successful commercialization of Chinese-developed biotech platforms in international markets<\/td><\/tr><tr><td><strong>Japanese Pharma Strategy<\/strong><\/td><td>Taisho&#8217;s move aligns with broader Japanese pharmaceutical industry focus on external innovation sourcing<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>RenNano platform competes with other nanobody discovery technologies from Ablynx (Sanofi) and Harbour BioMed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Stream Diversification:<\/strong> Platform licensing provides non-dilutive revenue alongside Biocytogen&#8217;s internal drug development programs<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Success with Taisho may attract additional licensing opportunities with other international pharmaceutical companies<\/li>\n\n\n\n<li><strong>Technology Validation:<\/strong> Partnership serves as third-party validation of RenNano platform&#8217;s capabilities and competitive advantages<\/li>\n\n\n\n<li><strong>Pipeline Synergies:<\/strong> Potential for future collaboration on specific therapeutic programs leveraging the licensed platform<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Strengthens Biocytogen&#8217;s position as a leading provider of advanced antibody discovery technologies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Biocytogen&#8217;s business development activities and strategic partnerships. Actual partnership outcomes and financial impacts may vary based on research results and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1519,1214,4547,2570],"class_list":["post-61993","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-sha-688796","tag-taisho-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen Licenses RenNano Antibody Platform to Japan&#039;s Taisho Pharmaceutical in Strategic Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen&#039;s proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61993\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Licenses RenNano Antibody Platform to Japan&#039;s Taisho Pharmaceutical in Strategic Partnership\" \/>\n<meta property=\"og:description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen&#039;s proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61993\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T11:31:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T11:31:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Licenses RenNano Antibody Platform to Japan&#8217;s Taisho Pharmaceutical in Strategic Partnership\",\"datePublished\":\"2026-03-31T11:31:57+00:00\",\"dateModified\":\"2026-03-31T11:31:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"SHA: 688796\",\"Taisho Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61993#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61993\",\"name\":\"Biocytogen Licenses RenNano Antibody Platform to Japan's Taisho Pharmaceutical in Strategic Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-31T11:31:57+00:00\",\"dateModified\":\"2026-03-31T11:31:58+00:00\",\"description\":\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61993\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61993#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Licenses RenNano Antibody Platform to Japan&#8217;s Taisho Pharmaceutical in Strategic Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Licenses RenNano Antibody Platform to Japan's Taisho Pharmaceutical in Strategic Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61993","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Licenses RenNano Antibody Platform to Japan's Taisho Pharmaceutical in Strategic Partnership","og_description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.","og_url":"https:\/\/flcube.com\/?p=61993","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T11:31:57+00:00","article_modified_time":"2026-03-31T11:31:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61993#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61993"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Licenses RenNano Antibody Platform to Japan&#8217;s Taisho Pharmaceutical in Strategic Partnership","datePublished":"2026-03-31T11:31:57+00:00","dateModified":"2026-03-31T11:31:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61993"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","HKG: 2315","SHA: 688796","Taisho Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61993#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61993","url":"https:\/\/flcube.com\/?p=61993","name":"Biocytogen Licenses RenNano Antibody Platform to Japan's Taisho Pharmaceutical in Strategic Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-31T11:31:57+00:00","dateModified":"2026-03-31T11:31:58+00:00","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with Taisho Pharmaceutical Co., Ltd., granting the Japanese pharmaceutical company access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for internal research and development programs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61993#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61993"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61993#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Licenses RenNano Antibody Platform to Japan&#8217;s Taisho Pharmaceutical in Strategic Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61993"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61993\/revisions"}],"predecessor-version":[{"id":61994,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61993\/revisions\/61994"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}